WEKO3
アイテム
{"_buckets": {"deposit": "86d89207-fce1-43ca-ae90-8630cfa8f1f7"}, "_deposit": {"created_by": 3, "id": "2932", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "2932"}, "status": "published"}, "_oai": {"id": "oai:kwmed.repo.nii.ac.jp:00002932", "sets": ["792"]}, "author_link": ["124960", "124962", "124961", "124957", "124959", "124958"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "143", "bibliographicPageStart": "135", "bibliographicVolumeNumber": "46", "bibliographic_titles": [{}, {"bibliographic_title": "Kawasaki medical journal", "bibliographic_titleLang": "en"}]}]}, "item_10001_description_34": {"attribute_name": "記事種別(英)", "attribute_value_mlt": [{"subitem_description": "Regular Article", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Kawasaki Medical Society"}]}, "item_10001_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.11482/KMJ-E202046135", "subitem_relation_type_select": "DOI"}}]}, "item_10001_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2020en/KMJ-E202046135.pdf"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2020en/KMJ-E202046135.pdf", "subitem_relation_type_select": "URI"}}]}, "item_10001_relation_35": {"attribute_name": "医中誌ID", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "2022017994", "subitem_relation_type_select": "ICHUSHI"}}]}, "item_10001_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA12685295", "subitem_source_identifier_type": "NCID"}, {"subitem_source_identifier": "AA12029005", "subitem_source_identifier_type": "NCID"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "03850234", "subitem_source_identifier_type": "ISSN"}, {"subitem_source_identifier": "24343404", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_text_32": {"attribute_name": "著者所属(英)", "attribute_value_mlt": [{"subitem_text_language": "en", "subitem_text_value": "Department of Breast and Thyroid Surgery, Kawasaki Medical School"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Breast and Thyroid Surgery, Kawasaki Medical School"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Pathology, St. Luke’s International Hospital"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Breast and Thyroid Surgery, Kawasaki Medical School"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Pathology, Kawasaki Medical School"}, {"subitem_text_language": "en", "subitem_text_value": "Department of Breast and Thyroid Surgery, Kawasaki Medical School"}]}, "item_10001_textarea_5": {"attribute_name": "抄録(英)", "attribute_value_mlt": [{"subitem_textarea_language": "en", "subitem_textarea_value": " A cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib (PAL), combined with endocrine therapy is frequently used for the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer. However, as predictors for the outcomes remain unclear, we retrospectively investigated them.\n A total of 36 patients with ER-positive, HER2-negative advanced breast cancer were treated using PAL plus endocrine therapy at our hospital. Treatment outcomes, objective response rates (ORR), progression-free survival (PFS) and post-treatment overall survival (OS) were analyzed. As possible predictive biomarkers, retinoblastoma protein (Rb), phosphorylated Rb (pRb) and different CDKs were immunohistochemically investigated using primary tumor tissues. Non-visceral metastasis, use of fulvestrant (FUL) and the 1st- or 2nd-line treatment were significant predictors for a better ORR (P = 0.0080, P = 0.0080 and P = 0.0080, respectively). No objective response (OR) was observed in patients with progesterone receptor (PR)-negative, CDK6-positive or cytosolic cyclin E1-positive tumors. Non-visceral metastasis and use of FUL were significant predictors for a better PFS (P = 0.0030 and P = 0.0443, respectively). The Cox proportional hazards model revealed that visceral metastasis (hazard ratio [HR], 4.9; P = 0.0019) and PR-negativity (HR, 3.2; P = 0.0411) were independent predictors for a poorer PFS. Nonvisceral metastasis, pRb-negativity and CDK6-negativity were significant predictors for a better OS (P = 0.0281, P = 0.0014 and P = 0.0396, respectively). The Cox proportional hazards model revealed that visceral metastasis (HR, 7.2; P = 0.0131) and pRb-positivity (HR, 18.5; P = 0.0060) were independent predictors for a poorer OS.\n In conclusion, PR-negativity and pRb-positivity in primary tumors may be independent predictors for PFS and OS, respectively. CDK6-positivity and cytosolic cyclin E1-positivity may be predictors for a poorer OS and ORR, respectively. Further investigation is needed to confirm these factors."}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "YAMAMOTO, Yutaka", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "124957", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OGATA, Ryohei", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "124958", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KANOMATA, Naoki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "124959", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KISHINO, Emi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "124960", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "MORIYA, Takuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "124961", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KUREBAYASH, Junichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "124962", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-10-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "KMJ-E202046135.pdf", "filesize": [{"value": "2.1 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2100000.0, "url": {"label": "PDF", "url": "https://kwmed.repo.nii.ac.jp/record/2932/files/KMJ-E202046135.pdf"}, "version_id": "45397dce-9b1c-41ea-bd9c-8fd300af5be0"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": " Palbociclib", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Predictors", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Response", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Progression-free survival", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Overall survival", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy", "subitem_title_language": "en"}]}, "item_type_id": "10001", "owner": "3", "path": ["792"], "permalink_uri": "https://kwmed.repo.nii.ac.jp/records/2932", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-10-21"}, "publish_date": "2022-10-21", "publish_status": "0", "recid": "2932", "relation": {}, "relation_version_is_last": true, "title": ["Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy"], "weko_shared_id": -1}
Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy
https://kwmed.repo.nii.ac.jp/records/2932
https://kwmed.repo.nii.ac.jp/records/293220fbccc3-d6f7-4f0d-9637-8d4d0f76da3e
名前 / ファイル | ライセンス | アクション |
---|---|---|
PDF (2.1 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-10-21 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Predictors for the outcomes of patients with estrogen receptor-positive, HER2-negative advanced breast cancer treated using palbociclib plus endocrine therapy | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
YAMAMOTO, Yutaka
× YAMAMOTO, Yutaka× OGATA, Ryohei× KANOMATA, Naoki× KISHINO, Emi× MORIYA, Takuya× KUREBAYASH, Junichi |
|||||
著者所属(英) | ||||||
en | ||||||
Department of Breast and Thyroid Surgery, Kawasaki Medical School | ||||||
著者所属(英) | ||||||
en | ||||||
Department of Breast and Thyroid Surgery, Kawasaki Medical School | ||||||
著者所属(英) | ||||||
en | ||||||
Department of Pathology, St. Luke’s International Hospital | ||||||
著者所属(英) | ||||||
en | ||||||
Department of Breast and Thyroid Surgery, Kawasaki Medical School | ||||||
著者所属(英) | ||||||
en | ||||||
Department of Pathology, Kawasaki Medical School | ||||||
著者所属(英) | ||||||
en | ||||||
Department of Breast and Thyroid Surgery, Kawasaki Medical School | ||||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Palbociclib | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Predictors | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Response | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Progression-free survival | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Overall survival | |||||
抄録(英) | ||||||
en | ||||||
A cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib (PAL), combined with endocrine therapy is frequently used for the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer. However, as predictors for the outcomes remain unclear, we retrospectively investigated them. A total of 36 patients with ER-positive, HER2-negative advanced breast cancer were treated using PAL plus endocrine therapy at our hospital. Treatment outcomes, objective response rates (ORR), progression-free survival (PFS) and post-treatment overall survival (OS) were analyzed. As possible predictive biomarkers, retinoblastoma protein (Rb), phosphorylated Rb (pRb) and different CDKs were immunohistochemically investigated using primary tumor tissues. Non-visceral metastasis, use of fulvestrant (FUL) and the 1st- or 2nd-line treatment were significant predictors for a better ORR (P = 0.0080, P = 0.0080 and P = 0.0080, respectively). No objective response (OR) was observed in patients with progesterone receptor (PR)-negative, CDK6-positive or cytosolic cyclin E1-positive tumors. Non-visceral metastasis and use of FUL were significant predictors for a better PFS (P = 0.0030 and P = 0.0443, respectively). The Cox proportional hazards model revealed that visceral metastasis (hazard ratio [HR], 4.9; P = 0.0019) and PR-negativity (HR, 3.2; P = 0.0411) were independent predictors for a poorer PFS. Nonvisceral metastasis, pRb-negativity and CDK6-negativity were significant predictors for a better OS (P = 0.0281, P = 0.0014 and P = 0.0396, respectively). The Cox proportional hazards model revealed that visceral metastasis (HR, 7.2; P = 0.0131) and pRb-positivity (HR, 18.5; P = 0.0060) were independent predictors for a poorer OS. In conclusion, PR-negativity and pRb-positivity in primary tumors may be independent predictors for PFS and OS, respectively. CDK6-positivity and cytosolic cyclin E1-positivity may be predictors for a poorer OS and ORR, respectively. Further investigation is needed to confirm these factors. |
||||||
書誌情報 |
en : Kawasaki medical journal 巻 46, p. 135-143, 発行日 2020 |
|||||
出版者 | ||||||
出版者 | Kawasaki Medical Society | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 03850234 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 24343404 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA12685295 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA12029005 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.11482/KMJ-E202046135 | |||||
記事種別(英) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Regular Article | |||||
医中誌ID | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | ICHUSHI | |||||
関連識別子 | 2022017994 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2020en/KMJ-E202046135.pdf | |||||
関連名称 | https://igakkai.kms-igakkai.com/wp/wp-content/uploads/2020en/KMJ-E202046135.pdf | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |